Is Blood a Drug?
Yes—at least in the regulatory sense.
Blood and blood components occupy an interesting place in U.S. law because the FDA regulates them both as biological products and as drugs. The two major federal statutes involved are the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act (FD&C Act).
That doesn't mean a unit of RBCs is treated exactly like a bottle of lisinopril sitting in the pharmacy.
Blood is a biologic: a complex product obtained from a human donor, collected, tested, processed, stored, labeled, distributed, and ultimately transfused into another person. FDA's Center for Biologics Evaluation and Research (CBER) regulates blood and blood components intended for transfusion and establishes standards governing their manufacture and safety.
And yes, in the eyes of federal law, blood components also fall within the regulatory framework applied to drugs.
Blood Is a Manufactured Product
One of the strange things about working in a blood bank is that we don't usually think of ourselves as working in manufacturing.
But from the FDA's perspective, that's exactly what much of blood banking is.
The regulatory definition of manufacturing encompasses much more than collecting a bag of blood. Testing, processing, preparation, labeling, storage, holding, and distribution can all fall within the manufacturing framework governing blood products. FDA consequently applies current Good Manufacturing Practice requirements specifically to blood and blood components.
Think about everything that has to happen before an RBC unit reaches a patient's IV:
A donor must meet eligibility requirements.
The donation has to be collected properly.
Required infectious-disease testing must be performed.
The component must be prepared correctly.
Its ABO/RhD type and other required information must be correct.
Storage temperature has to remain within specification.
Expiration dating has to be correct.
Any required modification—such as irradiation—has to occur.
The correct product has to be selected for the correct patient.
Compatibility testing has to be performed appropriately.
And the unit has to remain traceable throughout the entire process.
FDA oversight reaches across this system. CBER establishes and enforces standards for blood collection and manufacturing, inspects blood establishments, and monitors errors, accidents, and adverse events involving blood products.
Why Are Blood Banks So Obsessed With Documentation?
This helps explain one of the first things new blood bankers learn:
If it wasn't documented, it didn't happen.
Blood products exist inside a tightly controlled manufacturing and distribution system. Procedures aren't merely suggestions for how the technologist on duty prefers to perform a task. The blood bank has validated procedures describing how products are tested, prepared, modified, stored, selected, labeled, and issued.
When something deviates from those procedures, it may need to be investigated and documented.
That doesn't mean every mistake automatically gets reported to the FDA.
FDA's Biological Product Deviation reporting requirements apply to certain deviations or unexpected events involving manufacturing, testing, processing, labeling, storage, holding, or distribution when a distributed product may have had its safety, purity, or potency affected. Reportable events must generally be submitted as soon as possible and no later than 45 calendar days after the establishment obtains information indicating that a reportable event occurred.
If a problem is discovered and corrected before the affected product is distributed, FDA guidance specifically notes that it may require internal investigation and documentation without necessarily requiring a Biological Product Deviation Report.
So the real rule is closer to:
Investigate deviations. Document them. Then determine whether the event meets FDA reporting criteria.
What Does a Reportable Blood Bank Error Actually Look Like?
This isn't just theoretical.
FDA publishes summaries of Biological Product Deviation Reports submitted by transfusion services. In fiscal year 2023, transfusion services submitted reports involving:
products that were not irradiated when irradiation was required
incorrect ABO or RhD product selection
incorrect product selection
outdated products
failures involving compatibility testing
antibody-screen or antibody-identification errors
antigen-typing errors
ABO/RhD testing errors
incorrect or incomplete transfusion-service labeling.
In fact, FDA's FY2023 report recorded 126 transfusion-service reports involving a product that was not irradiated as required.
So imagine a patient has a documented requirement for irradiated cellular blood components.
The blood bank accidentally issues a nonirradiated unit.
The unit is transfused.
That isn't merely, "Oops, someone forgot to click the irradiated box."
A product that failed to meet the patient's required specifications was distributed and transfused. The blood bank has to investigate what happened, determine why its safeguards failed, assess the affected product and patient, and determine the applicable FDA reporting obligations.
That is one reason transfusion services build so many layers of computer warnings, historical attributes, special-requirement flags, product checks, SOPs, and second checks around seemingly simple tasks.
Does Every Hospital Blood Bank Get FDA Inspections?
There's another nuance here.
Not every hospital transfusion service is required to register with FDA. A transfusion service operating within a CLIA-certified facility that performs compatibility testing and transfusion but does not routinely collect or process blood products may qualify for an exemption from FDA blood-establishment registration.
Blood establishments that manufacture blood products are generally subject to FDA registration requirements, and licensed manufacturers face additional federal requirements.
So saying simply, "Every blood bank is FDA inspected because blood is a drug" isn't quite right.
But FDA regulation absolutely reaches deeply into transfusion medicine, including the manufacturing and distribution requirements governing blood components and the reporting obligations that can apply to hospital transfusion services.
What About Physician Orders?
Blood components are not treated like ordinary over-the-counter supplies that anyone can simply request from the laboratory.
Hospitals require appropriate clinical authorization for transfusion, and transfusion services have procedures governing routine orders, emergency release, massive transfusion protocols, and other urgent circumstances.
However, saying:
"Blood is legally a drug, therefore federal law requires a physician's prescription before the blood bank can release it"
isn't the best way to explain the relationship.
FDA's classification of blood components as drugs and biologics primarily drives requirements surrounding manufacture, safety, purity, potency, labeling, storage, distribution, and regulatory oversight.
The exact requirements for who may order or authorize transfusion—and how emergency transfusion is documented—also depend on hospital procedures, professional standards, accreditation requirements, and applicable state law.
That's why emergency-release RBCs can be issued before compatibility testing is complete when the clinical situation demands it. The process isn't "no paperwork, no blood." Rather, the transfusion service follows a specifically established emergency procedure that documents who authorized the transfusion and acknowledges the additional risk.
From Donor to Recipient
FDA oversight of blood begins long before a technologist receives a type-and-screen specimen.
It encompasses donor eligibility and screening, infectious-disease testing, collection, component preparation, storage, labeling, and distribution. FDA also regulates many of the products used to make this system work, including blood-collection systems, donor-testing assays, apheresis equipment, pathogen-reduction technology, and blood-establishment computer software.
That helps explain why transfusion medicine can sometimes feel less like a typical clinical laboratory department and more like a tiny pharmaceutical manufacturing operation hidden inside a hospital.
Every unit has a manufacturing history.
Every unit has defined storage requirements.
Every unit has an expiration date.
Every unit has labeling requirements.
Every unit must be traceable.
And when something goes wrong, the response can extend far beyond simply correcting a result in the LIS.
Blood may come from another human being, but once it enters the blood-supply system, it becomes one of the most tightly controlled biological products used in medicine.
0 comments:
Post a Comment